Payment overview · 2025
General Payments
$1,327.06
47 reported records · 9 companies
Healthcare provider profile · identity verified
Henry Rojas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARMEL, NY · NPI 1700970670
Verified facts
What the public records show
CMS Open Payments records show Henry Rojas, MD received $1,327.06 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $565.80 | 42.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $302.62 | 22.8% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $173.97 | 13.1% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.52 | 10.7% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $61.20 | 4.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.59 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.15 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.06 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.15 | 0.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,327.06 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $420.98 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $265.92 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $252.72 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $157.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $152.89 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $61.20 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.39 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.15 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 361 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 361 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
361 | 360 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
361 | 250 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
77 | 77 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 361 | 360 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 361 | 250 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 37 |
| Alprazolam | Alprazolam | 176 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 23 |
| Losartan Potassium | Losartan Potassium | 111 | 29 |
| Omeprazole | Omeprazole | 111 | 25 |
| Simvastatin | Simvastatin | 108 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 106 | 31 |
| Metformin Hcl | Metformin Hcl | 106 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 78 | 77 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 77 | 77 |
| Lisinopril | Lisinopril | 66 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 17 |
| Gabapentin | Gabapentin | 60 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 21 | 21 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,327.06 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, FARXIGA, KISUNLA, MOUNJARO, PAXLOVID, REXULTI, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error